FR3099156A1 - Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux - Google Patents
Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux Download PDFInfo
- Publication number
- FR3099156A1 FR3099156A1 FR1908485A FR1908485A FR3099156A1 FR 3099156 A1 FR3099156 A1 FR 3099156A1 FR 1908485 A FR1908485 A FR 1908485A FR 1908485 A FR1908485 A FR 1908485A FR 3099156 A1 FR3099156 A1 FR 3099156A1
- Authority
- FR
- France
- Prior art keywords
- carbonyl
- oxo
- oxy
- chromene
- bromobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 title claims description 21
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 title claims description 21
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 title claims description 13
- 239000003112 inhibitor Substances 0.000 title description 10
- 239000003795 chemical substances by application Substances 0.000 title description 2
- 230000001093 anti-cancer Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 229940002612 prodrug Drugs 0.000 claims abstract description 3
- 239000000651 prodrug Substances 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 239000012453 solvate Substances 0.000 claims abstract description 3
- -1 5-((2-bromobenzyl)oxy)-4-oxo-4H-chromene-2-carbonyl Chemical group 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- YPTJKHVBDCRKNF-UHFFFAOYSA-N 2',6'-Dihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=CC=C1O YPTJKHVBDCRKNF-UHFFFAOYSA-N 0.000 claims description 13
- 125000001041 indolyl group Chemical group 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 claims description 6
- 229960005190 phenylalanine Drugs 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- XUUUJAUVBDHXFJ-LJAQVGFWSA-N 5-[(2-bromophenyl)methoxy]-N-[(2S)-1-[2-(5-hydroxy-1H-indol-3-yl)ethylamino]-1-oxo-3-phenylpropan-2-yl]-4-oxochromene-2-carboxamide Chemical compound BrC1=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)N[C@H](C(=O)NCCC2=CNC3=CC=C(C=C23)O)CC2=CC=CC=C2)=O)C=CC=C1 XUUUJAUVBDHXFJ-LJAQVGFWSA-N 0.000 claims description 4
- VGJQLSYFQXCGJU-JOCHJYFZSA-N methyl (2R)-2-[[5-[(4-bromophenyl)methoxy]-4-oxochromene-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoate Chemical compound BrC1=CC=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)OC)=O)C=C1 VGJQLSYFQXCGJU-JOCHJYFZSA-N 0.000 claims description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- VNQSLBAGTCEQAK-UHFFFAOYSA-N 5-[(2,4-dibromophenyl)methoxy]-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxochromene-2-carboxamide Chemical compound BrC1=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)NCCC2=CNC3=CC=C(C=C23)OC)=O)C=CC(=C1)Br VNQSLBAGTCEQAK-UHFFFAOYSA-N 0.000 claims description 3
- SLKSGXKYMGBWSO-WJOKGBTCSA-N 5-[(4-bromophenyl)methoxy]-N-[(2R)-3-(1H-indol-3-yl)-1-[2-(1H-indol-3-yl)ethylamino]-1-oxopropan-2-yl]-4-oxochromene-2-carboxamide Chemical compound N1C=C(C2=CC=CC=C12)CCNC([C@@H](CC1=CNC2=CC=CC=C12)NC(=O)C=1OC2=CC=CC(=C2C(C=1)=O)OCC1=CC=C(C=C1)Br)=O SLKSGXKYMGBWSO-WJOKGBTCSA-N 0.000 claims description 3
- DBFAVFRKVPZODB-LJAQVGFWSA-N 5-[(4-bromophenyl)methoxy]-N-[(2S)-1-[2-(1H-indol-3-yl)ethylamino]-1-oxo-3-phenylpropan-2-yl]-4-oxochromene-2-carboxamide Chemical compound N1C=C(C2=CC=CC=C12)CCNC([C@H](CC1=CC=CC=C1)NC(=O)C=1OC2=CC=CC(=C2C(C=1)=O)OCC1=CC=C(C=C1)Br)=O DBFAVFRKVPZODB-LJAQVGFWSA-N 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 150000002148 esters Chemical group 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000014842 Multidrug resistance proteins Human genes 0.000 claims description 2
- 108050005144 Multidrug resistance proteins Proteins 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 130
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 238000005481 NMR spectroscopy Methods 0.000 description 66
- 239000000243 solution Substances 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
- 238000000132 electrospray ionisation Methods 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 238000004809 thin layer chromatography Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000001953 recrystallisation Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 238000001665 trituration Methods 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- WLDWSGZHNBANIO-UHFFFAOYSA-N 2',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC=C1O WLDWSGZHNBANIO-UHFFFAOYSA-N 0.000 description 7
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 7
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 6
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 5
- 229960001156 mitoxantrone Drugs 0.000 description 5
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000004777 chromones Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 2
- 229940097276 5-methoxytryptamine Drugs 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000001246 bromo group Chemical class Br* 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- JYMGZSFVGSGPDO-UHFFFAOYSA-N ethyl 5-[(4-bromophenyl)methoxy]-4-oxochromene-2-carboxylate Chemical compound C(C)OC(=O)C=1OC2=CC=CC(=C2C(C=1)=O)OCC1=CC=C(C=C1)Br JYMGZSFVGSGPDO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- KDFBGNBTTMPNIG-UHFFFAOYSA-N hydron;2-(1h-indol-3-yl)ethanamine;chloride Chemical compound Cl.C1=CC=C2C(CCN)=CNC2=C1 KDFBGNBTTMPNIG-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- XNFNGGQRDXFYMM-PPHPATTJSA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-PPHPATTJSA-N 0.000 description 2
- CEMZBWPSKYISTN-YFKPBYRVSA-N methyl (2s)-2-amino-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)C CEMZBWPSKYISTN-YFKPBYRVSA-N 0.000 description 2
- SWVMLNPDTIFDDY-FVGYRXGTSA-N methyl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-FVGYRXGTSA-N 0.000 description 2
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LHGCCAHOOWGBKW-UHFFFAOYSA-N 1,2-dibromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1Br LHGCCAHOOWGBKW-UHFFFAOYSA-N 0.000 description 1
- PWTFRUXTAFBWBW-UHFFFAOYSA-N 1,3-dibromo-5-(bromomethyl)benzene Chemical compound BrCC1=CC(Br)=CC(Br)=C1 PWTFRUXTAFBWBW-UHFFFAOYSA-N 0.000 description 1
- KYDFVPDKYUTYNN-UHFFFAOYSA-N 1-[2-[(2,4-dibromophenyl)methoxy]-6-hydroxyphenyl]ethanone Chemical compound BrC1=C(COC2=C(C(=CC=C2)O)C(C)=O)C=CC(=C1)Br KYDFVPDKYUTYNN-UHFFFAOYSA-N 0.000 description 1
- ZEBOEQXKHODFDT-UHFFFAOYSA-N 1-[2-[(2-bromophenyl)methoxy]-6-hydroxyphenyl]ethanone Chemical compound BrC1=C(COC2=C(C(=CC=C2)O)C(C)=O)C=CC=C1 ZEBOEQXKHODFDT-UHFFFAOYSA-N 0.000 description 1
- MBQYXLHWTJXKEK-UHFFFAOYSA-N 1-[2-[(3,5-dibromophenyl)methoxy]-6-hydroxyphenyl]ethanone Chemical compound BrC=1C=C(COC2=C(C(=CC=C2)O)C(C)=O)C=C(C=1)Br MBQYXLHWTJXKEK-UHFFFAOYSA-N 0.000 description 1
- RUBLCFRHGQTMRM-UHFFFAOYSA-N 1-[2-[(4-bromophenyl)methoxy]-6-hydroxyphenyl]ethanone Chemical compound CC(=O)C1=C(O)C=CC=C1OCC1=CC=C(Br)C=C1 RUBLCFRHGQTMRM-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- WBUUQZQZTKVJLZ-UHFFFAOYSA-N 2,4-dibromo-1-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1Br WBUUQZQZTKVJLZ-UHFFFAOYSA-N 0.000 description 1
- GHWYNNFPUGEYEM-UHFFFAOYSA-N 2,4-dibromo-1-methylbenzene Chemical compound CC1=CC=C(Br)C=C1Br GHWYNNFPUGEYEM-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- ZNAZPAUWVLFPJM-UHFFFAOYSA-N 5-[(2,4-dibromophenyl)methoxy]-4-oxochromene-2-carboxylic acid Chemical compound BrC1=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)O)=O)C=CC(=C1)Br ZNAZPAUWVLFPJM-UHFFFAOYSA-N 0.000 description 1
- ZIWIDQRFTYKHIA-UHFFFAOYSA-N 5-[(2-bromophenyl)methoxy]-4-oxochromene-2-carboxylic acid Chemical compound BrC1=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)O)=O)C=CC=C1 ZIWIDQRFTYKHIA-UHFFFAOYSA-N 0.000 description 1
- MWDYRODCMVAROB-UHFFFAOYSA-N 5-[(3,5-dibromophenyl)methoxy]-4-oxochromene-2-carboxylic acid Chemical compound BrC=1C=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)O)=O)C=C(C=1)Br MWDYRODCMVAROB-UHFFFAOYSA-N 0.000 description 1
- KNYCTDIICFUEDQ-UHFFFAOYSA-N 5-[(4-bromophenyl)methoxy]-4-oxochromene-2-carboxylic acid Chemical compound BrC1=CC=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)O)=O)C=C1 KNYCTDIICFUEDQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- YOAIRHFGLKORDQ-IBGZPJMESA-N OC([C@H](Cc1ccccc1)NC(C(Oc1c2c(OCc(cccc3)c3Br)ccc1)=CC2=O)=O)=O Chemical compound OC([C@H](Cc1ccccc1)NC(C(Oc1c2c(OCc(cccc3)c3Br)ccc1)=CC2=O)=O)=O YOAIRHFGLKORDQ-IBGZPJMESA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- MDIGAZPGKJFIAH-UHFFFAOYSA-N Serotonin hydrochloride Chemical compound Cl.C1=C(O)C=C2C(CCN)=CNC2=C1 MDIGAZPGKJFIAH-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- GGTBEWGOPAFTTH-GEMLJDPKSA-N [(2s,3s)-1-methoxy-3-methyl-1-oxopentan-2-yl]azanium;chloride Chemical compound Cl.CC[C@H](C)[C@H](N)C(=O)OC GGTBEWGOPAFTTH-GEMLJDPKSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WGNZRLMOMHJUSP-UHFFFAOYSA-N benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 WGNZRLMOMHJUSP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VCJZTATVUDMNLU-UHFFFAOYSA-N dibromomethylbenzene Chemical compound BrC(Br)C1=CC=CC=C1 VCJZTATVUDMNLU-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- CPRRDRMFXYSVJP-UHFFFAOYSA-N ethyl 5-[(2,4-dibromophenyl)methoxy]-4-oxochromene-2-carboxylate Chemical compound BrC1=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)OCC)=O)C=CC(=C1)Br CPRRDRMFXYSVJP-UHFFFAOYSA-N 0.000 description 1
- XNPVSSRFEFZLPC-UHFFFAOYSA-N ethyl 5-[(2-bromophenyl)methoxy]-4-oxochromene-2-carboxylate Chemical compound C(C)OC(=O)C=1OC2=CC=CC(=C2C(C=1)=O)OCC1=C(C=CC=C1)Br XNPVSSRFEFZLPC-UHFFFAOYSA-N 0.000 description 1
- LMIAYUMUAFSOFA-UHFFFAOYSA-N ethyl 5-[(3,5-dibromophenyl)methoxy]-4-oxochromene-2-carboxylate Chemical compound BrC=1C=C(COC2=C3C(C=C(OC3=CC=C2)C(=O)OCC)=O)C=C(C=1)Br LMIAYUMUAFSOFA-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- DBEYVIGIPJSTOR-FHWLQOOXSA-N fumitremorgin C Chemical class O=C1[C@@H]2CCCN2C(=O)[C@@H]2CC(C3=CC=C(C=C3N3)OC)=C3[C@H](C=C(C)C)N21 DBEYVIGIPJSTOR-FHWLQOOXSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000056858 human ABCG2 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- XNFNGGQRDXFYMM-UHFFFAOYSA-N hydron;methyl 2-amino-3-(1h-indol-3-yl)propanoate;chloride Chemical compound [Cl-].C1=CC=C2C(CC([NH3+])C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- KUGLDBMQKZTXPW-JEDNCBNOSA-N methyl (2s)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C(C)C KUGLDBMQKZTXPW-JEDNCBNOSA-N 0.000 description 1
- DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- le noyau A est non substitué ou substitué en position 2, 3, 4, 5 par un ou deux parmi H; F; Cl; Br; I; OR, avec R = Me, Et, Pr, i-Pr, n-Bu; O-CH2-(O-CH2CH2)n-O-CH3, avec n = 3, 4, 5, 6,
- Z est
- Y = -OH; -OMe; -OEt; -OPr; -NH2; -NHMe; -N(Me)2; -N(Me)OCH3; 3-(5-hydroxy)indolyl); 3-(5-méthoxy)indolyl); -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl) ; -NH(CH2)2-3-((5-méthoxy)indolyl) ; -NH-CH(R1)-COR2, avec R2choisi parmi :
- R1= H, ou
- au moins un agent anti-cancéreux ; et
- au moins un composé selon l’invention et défini ci-dessus.
EXEMPLE 1
Entrée | Position de Br | R 1 | Configuration absolue | Inhibition (%) | CI 50 (µM) | ||
1 µM | 10 µM | ||||||
SERIE 1 | |||||||
5a | 2 | -CH(CH3)CH2CH3 | S | 78 ± 9 | 143 ± 22 | 0,10 ± 0,01 | |
5c | 2 | -CH2CH(CH3)2 | S | 115 ± 17 | 101,5 ± 21,7 | 0,14 ± 0,04 | |
5d | 2 | -CH(CH3)2 | S | 87 ± 7 | 148,2 ± 6,7 | 0,05 ± 0,03 | |
5e | 2 | -CH2Ph | S | 100 ± 14 | 84,6 ± 2,0 | 0,10 ± 0,07 | |
5g | 2 | -CH2(3-indolyl) | S | 93,7 ± 17 | 39,7 ± 3,7 | n.d. | |
5f | 4 | -CH2Ph | S | 92 ± 15 | 114 ± 11 | 0,27 ± 0,11 | |
5h | 4 | -CH2(3-indolyl) | S | 92 ± 15 | 87,7 ± 12 | 0,48 ± 0,07 | |
5i | 4 | -CH2(3-indolyl) | R | 85 ± 12 | 96,3 ± 19 | 0,29 ± 0,05 | |
6a | 2 | -CH(CH3)CH2CH3 | S | 0,0 ± 0,7 | 1,6 ± 3,1 | n.d. | |
6d | 4 | -CH2Ph | S | 4,0 ± 0,7 | 6,5 ± 0,0 | n.d. | |
6e | 4 | -CH2(3-indolyl) | R | 6,1 ± 0,6 | 11,2 ± 2,0 | n.d. | |
SERIE 2 | |||||||
7a | 2 | -CH(CH3)CH2CH3 | S | 0,07 ± 0,01 | |||
7b | 2 | -CH(CH3)CH2CH3 | S | 0,07 ± 0,01 | |||
7c | 4 | -CH(CH3)CH2CH3 | S | 0,25 ± 0,10 | |||
7d | 4 | -CH(CH3)CH2CH3 | S | 0,11 ± 0,03 | |||
SERIE 3 | |||||||
7a | 2, 4 | H | / | / | 0,05 ± 0,01 | ||
7b | 3, 5 | H | / | / | 0,10 ± 0,01 | ||
MBL-II-141 | 4 | 0,13 ± 0,09 | |||||
Ko143 | 0,09 |
P-gp | MRP1 | BCRP | ||
entrée | [Inhibiteur] µM | Inhibition (%) | ||
5a (série 1) | 1 | |||
10 | / | |||
5c (série 1) | 1 | 7,0 ± 1,1 | 20,2 ± 2,7 | 114,5 |
10 | 4,8 ± 0,7 | 19,2 ± 2,2 | / | |
5d (série 1) | 1 | 7,9 ± 0,7 | 12,6 ± 1,3 | 86,6 |
10 | 6,5 ± 1,9 | 17,8 ± 0,9 | / | |
5e (série 1) | 1 | 4,9 ± 0,8 | 25,8 ± 0,8 | 100,2 |
10 | 5,7 ± 1,4 | 29,2 ± 1,5 | / | |
5f (série 1) | 1 | 6,4 ± 1,5 | 23,0 | 91,6 |
10 | 6,8 ± 1,4 | 19,0 | / | |
5g (série 1) | 1 | 7,4 ± 0,3 | 23,0 ± 2,5 | 93,7 |
10 | 5,3 ± 0,5 | 16,0 ± 2,5 | / | |
5h (série 1) | 1 | 7,4 ± 2,5 | 10,3 | 96,4 |
10 | 6,6 ± 1,4 | 17,4 | / | |
5i (série 1) | 1 | 7,2 ± 1,3 | 11,9 | 84,8 |
10 | 6,1± 1,1 | 12,6 | / | |
6a (série 1) | 1 | 7,8 1,8 | 17,1 | / |
10 | 7,9 ± 2,3 | 13,1 ± 2,4 | / | |
6b (série 1) | 1 | 7,7 ± 1,9 | 21,9 ± 4,6 | / |
10 | 7,1 ± 0,6 | 20,6 ± 1,2 | / | |
6c (série 1) | 1 | 7,7 ± 2,0 | 20,0 ± 3,7 | / |
10 | 6,3 ± 1,4 | 18,1 ± 1,2 | / | |
7a (série 2) | 1 | 0,1 ± 0,0 | 11,1 ± 0,8 | 84,8 ± 7,4 |
10 | 0,2 ± 0,0 | 10,8 ± 2,8 | / | |
7b (série 2) | 1 | 1,7 ± 2,4 | 10,3 ± 0,7 | 82,5 ± 9,7 |
10 | 2,4 ± 0,5 | ± 0,6 | / | |
7c (série 2) | 1 | 2,4 ± 2,1 | 11,5 ± 0,4 | 72,4 ± 7,1 |
10 | 10,6 ± 0,3 | 15,3 ± 1,5 | / | |
7d (série 2) | 1 | 3,6 ± 0,2 | 10,9 ± 1,4 | 52,3 ± 5,1 |
10 | 5,9 ± 0,1 | 14,7 ± 1,0 | / |
Claims (6)
- – Composé de formule (I) :
(I)
ou énantiomère, sel, solvate ou promédicament pharmaceutiquement acceptable de ce composé, ou un mélange de ceux-ci,
formule dans laquelle :- le noyau A est non substitué ou substitué en position 2, 3, 4, 5 par un ou deux parmi H; F; Cl; Br; I; OR, avec R = Me, Et, Pr, i-Pr, n-Bu; O-CH2-(O-CH2CH2)n-O-CH3, avec n = 3, 4, 5, 6,
- Z est
- Y = -OH; -OMe; -OEt; -OPr; -NH2; -NHMe; -N(Me)2; -N(Me)OCH3; 3-(5-hydroxy)indolyl); 3-(5-méthoxy)indolyl); -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl) ; -NH(CH2)2-3-((5-méthoxy)indolyl); -NH-CH(R1)-COR2, avec R2choisi parmi :
- R1= H, ou
à l’exception des composés :
la 5-(4-bromobenzyloxy)-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
la 5-benzyloxy-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
la 5-(2-bromobenzyloxy)-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
la 5-(3-bromobenzyloxy)-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
la 5-(2-fluorobenzyloxy)-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
la 5-(3-fluorobenzyloxy)-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
la 5-(4-fluorobenzyloxy)-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
le 5-(3,4-difluorobenzyloxy)-2-(2-(5-méthoxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
la 5-(4-bromobenzyloxy)-2-(2-(5-hydroxyindolyl)éthyl-1-carbonyl)-4H-chroméne-4-one,
et les composés avec simultanément Br en position 4 du noyau A, R1= CH(CH3)2ou CH2CH(CH3)2ou CH(CH3)CH2CH3et Y = -OH ou –OMe ou 3-(5-méthoxy)indolyl). - – Composé selon la revendication 1, caractérisé par le fait que le noyau A est substitué en position 2, 3, 4, 5 par un ou deux Br et Y = -OH; -OMe; 3-(5-méthoxy)indolyl); -NH-(CH2)2-(3-indolyl); -NH(CH2)2-3-((5-hydroxy)indolyl) ; -NH(CH2)2-3-((5-méthoxy)indolyl) ; -NH-CH(R1)-COR2, R1et R2étant tels que définis à la revendication 1.
- – Composé selon l’une des revendications 1 et 2 choisi parmi :
le (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-alloisoleucinate de méthyle ;
le (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-leucinate de méthyle ;
le (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-valinate de méthyle ;
le (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-phénylalaninate de méthyle ;
le (5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-phénylalaninate de méthyle ;
le (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-tryptophanate de méthyle ;
le (5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-tryptophanate de méthyle ;
le (5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-D-tryptophanate de méthyle ;
la (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-alloisoleucine ;
la (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-phénylalanine ;
la (5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-phénylalanine ;
le (5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-D-tryptophane ;
le (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-alloisoleucyl-L-valinate de méthyle ;
le (5-((2-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-alloisoleucyl-L-leucinate de méthyle ;
le (5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-alloisoleucyl-L-valinate de méthyle ;
le (5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carbonyl)-L-alloisoleucyl-L-leucinate de méthyle ;
le (S)-5-((2-bromobenzyl)oxy)-N-(1-((2-(5-hydroxy-1H-indol-3-yl)éthyl)amino)-1-oxo-3-phénylpropan-2-yl)-4-oxo-4H-chromène-2-carboxamide ;
le (S)-N-(1-((2-(1H-indol-3-yl)éthyl)amino)-1-oxo-3-phénylpropan-2-yl)-5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carboxamide ;
le (R)-N-(1-((2-(1H-indol-3-yl)éthyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-5-((4-bromobenzyl)oxy)-4-oxo-4H-chromène-2-carboxamide ;
le 5-((2,4-dibromobenzyl)oxy)-N-(2-(5-méthoxy-1H-indol-3-yl)éthyl)-4-oxo-4H-chromène-2-carboxamide, et
le ((3,5-dibromobenzyl)oxy)-N-(2-(5-méthoxy-1H-indol-3-yl)éthyl)-4-oxo-4H-chromène-2-carboxamide. - – Procédé d’obtention des composés selon l’une des revendications 1 à 3 caractérisé par le fait qu’il comprend les étapes :
(a) on fait réagir un composé alkylant de formule
[Cham. 62]
;
(b) on fait réagir l’intermédaire obtenu à l’étape (a), avec l’oxalate de diéthyle de formule
(c) on fait réagir l’intermédiaire obtenu à l’étape (b), par une réaction d’hydrolyse de la fonction ester à la température de 50°C, en milieu acide ou basique, dans un solvant THF/éthanol/eau (3:1:1,5) afin d’obtenir l’intermédiaire de formule
(d) on fait réagir l’intermédiaire obtenu à l’étape (c) avec un composé de couplage de formule
- – Composé selon l’une des revendications 1 à 3, pour son utilisation dans l’inhibition de la protéine de résistance multi-drogues du cancer du sein (Breast Cancer Resistance Protein BCRP/ABCG2).
- – Composition pharmaceutique comprenant :
- au moins un agent anti-cancéreux ; et
- au moins un composé selon l’une des revendications 1 à 3.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1908485A FR3099156B1 (fr) | 2019-07-25 | 2019-07-25 | Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux |
CN202080053589.5A CN114206904A (zh) | 2019-07-25 | 2020-06-01 | 选择性bcrp/abcg2转运蛋白抑制剂作为消除抗癌药物耐药性的药物 |
JP2022505245A JP2022541334A (ja) | 2019-07-25 | 2020-06-01 | 抗がん剤への耐性を消失させるための剤としての選択的bcrp/abcg2トランスポーター阻害剤 |
EP20742915.0A EP4003969A1 (fr) | 2019-07-25 | 2020-06-01 | Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux |
CA3148804A CA3148804A1 (fr) | 2019-07-25 | 2020-06-01 | Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux |
US17/629,966 US20220267289A1 (en) | 2019-07-25 | 2020-06-01 | Selective bcrp/abcg2 transporter inhibitors as agents to abolish resistance to anti-cancer agents |
PCT/IB2020/055168 WO2021014229A1 (fr) | 2019-07-25 | 2020-06-01 | Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1908485 | 2019-07-25 | ||
FR1908485A FR3099156B1 (fr) | 2019-07-25 | 2019-07-25 | Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3099156A1 true FR3099156A1 (fr) | 2021-01-29 |
FR3099156B1 FR3099156B1 (fr) | 2022-01-28 |
Family
ID=67999957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1908485A Active FR3099156B1 (fr) | 2019-07-25 | 2019-07-25 | Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220267289A1 (fr) |
EP (1) | EP4003969A1 (fr) |
JP (1) | JP2022541334A (fr) |
CN (1) | CN114206904A (fr) |
CA (1) | CA3148804A1 (fr) |
FR (1) | FR3099156B1 (fr) |
WO (1) | WO2021014229A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113480410A (zh) * | 2021-07-07 | 2021-10-08 | 南京伊派森化学科技有限公司 | 一种2,4-二溴苯甲醇的合成方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2602467C (fr) * | 2005-03-30 | 2014-09-02 | Kabushiki Kaisha Yakult Honsha | Inhibiteurs de bcrp/abcg2 |
WO2009070331A2 (fr) * | 2007-11-27 | 2009-06-04 | Stc.Unm | Composés et procédés d'inhibition sélective des transporteurs abcb1, abcc1 et abcg2 et pour le traitement de cancers, notamment de cancers résistants aux médicaments et pour le dosage par cytométrie en flux à haut débit pour détecter les inhibiteurs sélectifs |
US20100249089A1 (en) * | 2007-12-03 | 2010-09-30 | Kabushiki Kaisha Yakult Honsha | Abcg2 inhibitor |
-
2019
- 2019-07-25 FR FR1908485A patent/FR3099156B1/fr active Active
-
2020
- 2020-06-01 CA CA3148804A patent/CA3148804A1/fr active Pending
- 2020-06-01 WO PCT/IB2020/055168 patent/WO2021014229A1/fr active Application Filing
- 2020-06-01 EP EP20742915.0A patent/EP4003969A1/fr active Pending
- 2020-06-01 CN CN202080053589.5A patent/CN114206904A/zh active Pending
- 2020-06-01 JP JP2022505245A patent/JP2022541334A/ja active Pending
- 2020-06-01 US US17/629,966 patent/US20220267289A1/en active Pending
Non-Patent Citations (19)
Title |
---|
ALLEN, J. D.VAN LOEVEZIJN, A.LAKHAI, J. M.VAN DER VALK, M.VAN TELLINGEN, O.REID, G.SCHELLENS, J. H. M.KOOMEN, G.-J.SCHINKEL, A. H.: "Potent and Specific Inhibition of the Breast Cancer Résistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C.", MOL. CANCER THER., vol. 1, no. 6, 2002, pages 417, XP002247386 |
AMANDA DO ROCIO ANDRADE PIRES ET AL: "New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 122, 2016, pages 291 - 301, XP029705909, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2016.05.053 * |
BORST, P.ELFERINK, R. O.: "Mammalian ABC Transporters in Health and Disease", ANNU. REV. BIOCHEM., vol. 71, no. 1, 2002, pages 537 - 592, XP002959942, doi:10.1146/annurev.biochem.71.102301.093055 |
BUGDE, P.BISWAS, R.MERIEN, F.LU, J.LIU, D.-X.CHEN, M.ZHOU, S.LI, Y.: "The Therapeutic Potential of Targeting ABC Transporters to Combat Multi-Drug Résistance", EXPERT OPIN. THER. TARGETS, vol. 21, no. 5, 2017, pages 511 - 530 |
ECKFORD, P. D. W.SHAROM, F. J.: "ABC Efflux Pump-Based Résistance to Che-motherapy Drugs", CHEM. REV., vol. 109, no. 7, 2009, pages 2989 - 3011 |
EVELYN WINTER ET AL: "Structure-Activity Relationships of Chromone Derivatives toward the Mechanism of Interaction with and Inhibition of Breast Cancer Resistance Protein ABCG2", JOURNAL OF MEDICINAL CHEMISTRY,, vol. 56, no. 24, 2013, pages 9849 - 9860, XP002784593, DOI: 10.1021/JM401649J * |
GLAUCIO VALDAMERI ET AL: "Substituted Chromones as Highly Potent Nontoxic Inhibitors, Specific for the Breast Cancer Resistance Protein", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 2, 2012, pages 966 - 970, XP055649683, ISSN: 0022-2623, DOI: 10.1021/jm201404w * |
HÉNIN, E.HONORÂT, M.GUITTON, J.DI PIETRO, A.PAYEN, L.TOD, M.: "Pharmacokinetic Interactions in Mice between Irinotecan and MBL-11-141, an ABCG2 Inhibitor: Irinotecan MBLI-11-141 Interaction", BIOPHARM. DRUG DISPOS, 2017 |
HONORAT, M.GUITTON, J.GAUTHIER, C.BOUARD, C.LECERF-SCHMIDT, F.PERES, B.TERREUX, R.GERVOT, H.RIOUFOL, C.BOUMENDJEL, A. ET AL.: "MBL-II-141, a Chromone Derivative, Enhances Irinotecan (CPT-11) Anticancer Efficiency in ABCG2-Positive Xenografts", ONCOTARGET, vol. 5, no. 23, 2014, pages 11957 - 11970 |
LECERF-SCHMIDT, F.PERES, B.VALDAMERI, G.GAUTHIER, C.WINTER, E.PAYEN, L.DI PIETRO, A.BOUMENDJEL, A.: "ABCG2: Recent Discovery of Potent and Highly Selective Inhibitors", FUTURE MED. CHEM., vol. 5, no. 9, 2013, pages 1037 - 1045 |
LESLIE, E. M.DEELEY, R. G.COLE, S. P. C.: "Multidrug Résistance Proteins: Role of P-Glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in Tissue Defense", TOXICOL. APPL. PHARMACOL., vol. 204, no. 3, 2005, pages 216 - 237, XP004858694, doi:10.1016/j.taap.2004.10.012 |
LI, Y.HAYMAN, E.PLESESCU, M.PRAKASH, S. R.: "Synthesis of Potent BCRP Inhibitor-Kol43", TETRAHEDRON LETT., vol. 49, no. 9, 2008, pages 1480 - 1483, XP022439753, doi:10.1016/j.tetlet.2007.12.130 |
LINTON, K. J.: "Structure and Function of ABC Transporters", PHYSIOLOGY, vol. 22, no. 2, 2007, pages 122 - 130 |
LIU, K.ZHU, J.HUANG, Y.LI, C.LU, J.SACHAR, M.LI, S.MA, X.: "Metabolism of KO 143, an ABCG2 Inhibitor", DRUG METAB. PHARMACOKINET., vol. 32, no. 4, 2017, pages 193 - 200 |
PIRES, A. DO R. A.LECERF-SCHMIDT, F.GURAGOSSIAN, N.PAZINATO, J.GOZZI, G. J.WINTER, E.VALDAMERI, G.VEALE, A.BOUMENDJEL, A.DI PIETRO: "New, Highly Potent and Non- Toxic, Chromone Inhibitors of the Human Breast Cancer Résistance Protein ABCG2", EUR. J. MED. CHEM., vol. 122, 2016, pages 291 - 301, XP029705909, doi:10.1016/j.ejmech.2016.05.053 |
SHAROM, F. J.: "ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance", PHARMACOGENOMICS, vol. 9, no. 1, 2008, pages 105 - 127, XP055038488, doi:10.2217/14622416.9.1.105 |
VALDAMERI, G.GENOUX-BASTIDE, E.PERES, B.GAUTHIER, C.GUITTON, J.TERREUX, R.WINNISCHOFER, S. M. B.ROCHA, M. E. M.BOUMENDJEL, A.DI PI: "Substituted Chromones as Highly Potent Nontoxic Inhibitors, Specific for the Breast Cancer Résistance Protein", J. MED. CHEM., vol. 55, no. 2, 2012, pages 966 - 970 |
WEIDNER, L. D.ZOGHBI, S. S.LU, S.SHUKLA, S.AMBUDKAR, S. V.PIKE, V. W.MULDER, J.GOTTESMAN, M. M.INNIS, R. B.HALL, M. D.: "The Inhibitor Ko143 Is Not Spécifié for ABCG2", J. PHARMACOL. EXP. THER., vol. 354, no. 3, 2015, pages 384 - 393 |
WINTER, E.LECERF-SCHMIDT, F.GOZZI, G.PERES, B.LIGHTBODY, M.GAUTHIER, C.OZVEGY-LACZKA, C.SZAKACS, G.SARKADI, B.CRECZYNSKI-PASA, T. : "Structure-Activity Relationships of Chromone Derivatives toward the Mechanism of Interaction with and Inhibition of Breast Cancer Résistance Protein ABCG2", J. MED. CHEM., vol. 56, no. 24, 2013, pages 9849 - 9860, XP002784593, doi:10.1021/jm401649j |
Also Published As
Publication number | Publication date |
---|---|
JP2022541334A (ja) | 2022-09-22 |
EP4003969A1 (fr) | 2022-06-01 |
CA3148804A1 (fr) | 2021-01-28 |
CN114206904A (zh) | 2022-03-18 |
US20220267289A1 (en) | 2022-08-25 |
FR3099156B1 (fr) | 2022-01-28 |
WO2021014229A1 (fr) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0950047B1 (fr) | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant | |
EP0477049B1 (fr) | Dérivés d'amido-3 pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
JP2023109922A (ja) | 癌を治療する方法 | |
EP2456754B1 (fr) | Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog | |
CA2696237C (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
CA2679411A1 (fr) | Composes actifs sur ppar | |
EP3630759B1 (fr) | Composés inhibiteurs des canaux ioniques pour le traitement du cancer | |
WO1999015525A1 (fr) | Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant | |
JP2009513523A (ja) | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 | |
ES2684334T3 (es) | Compuesto de amida | |
CA3097622A1 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
AU2018235266B2 (en) | Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | |
FR3099156A1 (fr) | Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux | |
KR20110023895A (ko) | 치환된 7-술파닐메틸, 7-술피닐메틸 및 7-술포닐메틸 인돌, 및 그의 용도 | |
CA2752198C (fr) | Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique | |
EP2396320B1 (fr) | Derives de 3-benzofuranyl-indol-2-one substitues en position 3, leur preparation et leur application en therapeutique | |
CN116802176A (zh) | 羟吲哚及其使用方法 | |
JP2022518526A (ja) | カルバメート誘導体およびその使用 | |
Kamiyama et al. | Monamidocin, a Novel Fibrinogen Receptor Antagonist II. Biological Activity and Structure-activity Relationships | |
CN115960032A (zh) | 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途 | |
WO2023094734A1 (fr) | Ligands ciblant spécifiquement les transporteurs vésiculaires du glutamate pour l'imagerie à super-résolution | |
WO2011007091A1 (fr) | Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20210129 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
TQ | Partial transmission of property |
Owner name: UNIVERSITE CLAUDE BERNARD LYON 1, FR Effective date: 20220705 Owner name: CNRS - CENTRE NATIONAL DE LA RECHERCHE SCIENTI, FR Effective date: 20220705 Owner name: UNIVERSITE GRENOBLE ALPES, FR Effective date: 20220705 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |